Company Description
BioLingus in an exempted company with limited liability incorporated under the laws of the Cayman Islands, which is structured as a holding company whose main business operations are conducted through our subsidiaries in Switzerland and to a lesser extent, HK SAR, the People’s Republic of China and Australia.
We are a biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins.
The main peptide used to improve the technology was exenatide, which was the first commercial glucagon-like peptide (GLP-1) receptor protein product and is routinely used to treat type 2 diabetes.
During our first series of studies with exenatide, the sublingual dose required was almost 200 times the injectable dose to achieve a similar effect.
After 2 to 3 years of extensive development, we were able to reduce this ratio to 5 to 10, and we now have a “platform” of formulations (the “BioLingus Platform”) and expertise on how formulations should be designed for better performance.
| Country | Switzerland |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Yves Decadt |
Contact Details
Address: Grossmatt 6 Hergiswil , NW CH-6052 Switzerland | |
| Phone | +41786645430 |
| Website | biolingus.ch |
Stock Details
| Ticker Symbol | SUBL |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001966522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yves Decadt | Chief Executive Office and Chairman and director |
| Sai Ying Thomas Ko | Technical Advisor and director |
| Chun Pong Hui | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Dec 19, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Dec 18, 2023 | UPLOAD | Filing |
| Dec 13, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Nov 9, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 27, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 21, 2023 | UPLOAD | Filing |
| Jul 13, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jul 10, 2023 | UPLOAD | Filing |
| Jun 30, 2023 | F-1 | Registration statement for certain foreign private issuers |